null

Today, Mammoth Biosciences announced their series C and D at more than a $1B valuation. Mammoth is a startup story that Founders should be following because there is so much to learn from their path from the lab to unicorn status. At no other time in modern history has the need for science to lead our society toward a better future been more apparent and immense. We can meet this need by investing in the next generation of tech-bio companies like Mammoth.

NFX led Mammoth’s Pre-Seed and Seed rounds, co-led the Series A, and has invested in every round including today’s Series D. We even helped them name the company. Mammoth is the poster child for the NFX strategy of using network effects to build bio platforms — this approach to building tech-bio businesses should allow them to get 10x the size of a normal bio company. It’s also a great example of how NFX Bio supports Scientist-Founders as they become great Founders and CEOs after they leave the lab.

Listen in with Omri Drory, head of NFX Bio, and Partner James Currier as they take an inside look with Mammoth’s Co-Founder & CEO Trevor Martin at his journey from idea to unicorn — for the benefit of up-and-coming Scientist-Founders worldwide.

(0:00) Introduction and overview of Mammoth Biosciences (1:46) Understanding the scale and size of Mammoth Biosciences (3:27) The evolution and expansion of CRISPR protein families (6:02) Announcement of Mammoth's series D financing and journey of the company (9:11) The potential impact and challenges of Mammoth Biosciences (11:10) Mammoth's partnerships and commitment to building products (14:13) Recollection of the beginnings of Mammoth Biosciences (17:37) Advice for aspiring scientist founders (22:15) The role of the team in startup success and the future of Mammoth Biosciences (24:02) Introduction of new team member and reflection on Mammoth's journey (26:19) Celebrating series D success and closing remarks